Abstract
Abstract In July, the NCI will launch NCI-MATCH, a large basket trial that groups cancer patients into phase II drug trials based on genetic alterations in their tumors. The trial, and others like it, may eventually lead to cancer drug approvals based on a tumor's genomic profile rather than its tissue of origin.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
